负载NY-ESO-1多肽的树突状细胞激发特异性细胞毒性T淋巴细胞反应

doi:10.3969/j.issn.1671-167X.2017.05.017

摘要/Abstract

摘要： 目的探讨以NY-ESO-1为靶抗原、树突状细胞(dendritic cell, DCs)为抗原载体激发特异性细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTLs)反应的能力,以明确特异性CTLs的抗肿瘤免疫功能。方法在临床前实验基础上选择2014年11月至2015年10月于中国医学科学院肿瘤医院治疗的符合入选标准的15例Ⅱ~Ⅲ期HLA-A0201⁺NY-ESO-1⁺胃癌患者外周血,分离单个核细胞 (peripheral blood mononuclear cells, PBMCs) 和外周血淋巴细胞(peripheral blood lymphocytes, PBLs), 并诱导出成熟DCs (mature dendritic cell, mDCs);将人工合成的NY-ESO-1多肽负载mDCs后通过流式细胞仪(flow cytometry,FCM)分析细胞表型,检测体外反复致敏PBLs后负载NY-ESO-1的DCs激发特异性CTLs的能力以及CTLs对NY-ESO-1⁺胃癌细胞的体外杀伤活性,同时患者回输CTLs细胞,每2周1次,共回输2次,检测回输前后患者外周血细胞因子和特异性CTLs水平变化。结果采用FCM分析DCs细胞表型显示HLA-DR⁺CD11c⁺细胞为93.6%±1.2%,其中CD80⁺细胞为87.3%±3.6%,CD83⁺细胞为82.8%±2.5%,CD86⁺细胞为93.4%±6.4%。患者外周血分离的PBLs经NY-ESO-1多肽负载的DCs反复诱导后,细胞不断增殖,其中未负载多肽的DCs也能促进PBLs增殖,但细胞增殖指数(proliferation index, PI)明显低于负载多肽的DCs,两者比较差异有统计学意义(P<0.05)。负载NY-ESO-1多肽DCs诱导的NY-ESO-1多肽特异性的CTLs比例较未负载NY-ESO-1多肽DCs诱导的对照组明显升高(5.2%±1.2% vs. 0.4%±0.1%,P<0.05),且致敏后CTLs对NY-ESO-1⁺胃癌细胞及负载NY-ESO-1⁺多肽T2靶细胞的杀伤率明显高于对照组。输注CTLs细胞后,患者体内血清中细胞因子IFN-γ、IL-2、IL-12水平较治疗前显著升高[(132.9±10.2) μg/L vs. (46.4±3.1) μg/L; (101.3±6.4) μg/L vs. (26.7±1.2) μg/L; (51.3±2.6) μg/L vs. (26.4±1.1) μg/L; P均<0.05],且患者外周血特异性CTLs细胞比例明显升高。结论负载NY-ESO-1多肽的DCs体内外均具有激发特异性CTLs反应的能力,可诱导明显的抗肿瘤免疫效应。

关键词: T淋巴细胞, 细胞毒性, 免疫, 抗原, 肽类, 免疫治疗, 数突状细胞, NY-ESO-1多肽

Abstract: Objective: To explore the potential of autologous dendritic cells (DCs) pulsed with caner/testis antigen NY-ESO-1 peptides in inducing specific cytotoxic T lymphocyte (CTLs) response and antineoplastic immune function of specific CTLs. Methods: Fifteen patients with Ⅱ to Ⅲ stage positive HLA-A0201⁺ and NY-ESO-1⁺were enrolled in the Cancer Hospital Chinese Academy of Medical Sciences on the basis of preclinical experiments from November 2014 to October 2015, and their peripheral blood mononuclear cells (PBMCs) and peripheral blood lymphocytes (PBLs) were isolated. The PBMCs were induced into DCs and pulsed with NY-ESO-1 peptide. The phenotypes of DCs were stained with antibodies against HLA-DR⁺CD11c⁺,CD80⁺,CD83⁺ and CD86⁺, and subsequently analyzed by multichannel flow cytometry (FCM). The killing effects of CTLs pulsed with HLA-A0201-binding peptide NY-ESO-1 and the potential of autologous DCs pulsed with NY-ESO-1 peptides in inducing specific cytotoxic T lymphocytes (CTLs) responses were determined. The patients were administered two infusions of auto-logous CTLs for 1 time every two weeks. The total infusion was with 2 times. The immunological responses and clinical responses were examined in 1 week after the final administration. Results: The immunophenotype of DCs pulsed with NY-ESO-1 peptide was analyzed, HLA-DR⁺CD11c⁺ cells (93.6%±1.2%), CD80⁺ cells (87.3%±3.6%), CD83⁺cells (82.8%±2.5%) and CD86⁺ cells (93.4%±6.4%). PBLs isolated from patients primed by DCs pulsed with NY-ESO-1 peptide proliferated continuously and the proliferation index (PI) of the PBLs were analyzed. There was significant difference between the DCs loaded with polypeptides and those unloaded, though it could promote the proliferation of PBLs, but the PI was significantly lower than that of the DCs loaded with NY-ESO-1 peptide (P<0.05). The average percentage of special CTLs primed by DCs pulsed with NY-ESO-1 peptides was significantly higher than that in the control group (5.2%±1.2% vs. 0.4%±0.1%). CTLs induced by NY-ESO-1 pulsed DCs exerted a stronger killing effect on T2 cell line pulsed with NY-ESO-1 peptide than that in the control group at the ratio of E (effect) to T (target) as 30︰1, P<0.05. The cytokine levels in the patients’sera such as IFN-γ, IL-2 and IL-12 were increased after treatments [(132.9±10.2) μg/L vs. (46.4±3.1) μg/L; (101.3±6.4) μg/L vs. (26.7±1.2) μg/L; (51.3±2.6) μg/L vs. (26.4±1.1) μg/L; all P<0.05], and the percentages of antigen-specific CD8⁺IFN-γ⁺ increased in these patients (P<0.01). Conclusion:Auto-DCs pulsed with NY-ESO-1 peptides can induce the proliferation of allogenic CTLs, which elicit specific immune responses ex vivo or in vivo, and boost anticancer immunity markedly.

Key words: T-lymphocytes, cytotoxic, Immunity, Antigens, Peptides, Immunotherapy, Dendritic cell, NY-ESO-1 peptide

中图分类号:

R730.51

刘静维, 卢戌, 杨照敏, 邓丽娟, 杨林. 负载NY-ESO-1多肽的树突状细胞激发特异性细胞毒性T淋巴细胞反应[J]. 北京大学学报(医学版), 2017, 49(5): 840-846.

LIU Jing-wei, LU Xu, YANG Zhao-min, DENG Li-juan, YANG Lin. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide[J]. Journal of Peking University(Health Sciences), 2017, 49(5): 840-846.

参考文献

[1] Varadhachary G, Ajani JA. Gastric cancer[J].Clin Adv Hematol Oncol, 2005, 3(2): 118-124.
[2] Ajani JA.Evolving chemotherapy for advanced gastric cancer[J].Oncologist, 2005, 10(3): 49-58.
[3] Yoshihara M, Hiyama T, Yoshida S, et al.Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study[J].Scand J Gastroenterol, 2007, 42(6): 760-764.
[4] Larmonier N, Fraszczak J, Lakomy D, et a1.Killer dendritic cells and their potential for cancer immunotherapy[J].Cancer Immunol Immunother, 2010, 59(1): 1-11.
[5] Rosenberg SA, Restifo NP, Yang JC, et a1. Adoptive cell transfer:a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008, 8(4): 299-308.
[6] Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses [J] . Proc Natl Acad Sci USA, 2003, 100(15): 8862-8867.
[7] Simone K, Cristina B, Judith F, et al. Rapid generation of NY-ESO-1-specific CD4 + T HELPER 1 cells for adoptive T-cell therapy [J]. OncoImmunology, 2015, 4(5): e1002723.
[8] Park TS, Groh EM, Patel K, et al. Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers[J].J Immunother, 2016, 39(1): 1-7.
[9] Scanlan M J, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodoma in testis-specific gene (BRDT) as a new CT gene, CT9 [J]. Cancer Lett, 2000, 150(2): 155-164.
[10] Luo G, Huang S, Xie X, et al. Expression of cancer-testis genes in human hepatocellular carcinomas [J] . Cancer Immun, 2002, 19(2): 11.
[11] Ghafouri-Fard S, Shamsi R, Seifi-Alan M, et al. Cancer-testis genes as candidates for immunotherapy in breast cancer[J]. Immunotherapy, 2014, 6(2): 165-179.
[12] Lee HJ, Kim JY, Song IH, et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis[J]. Oncology, 2015, 89(6): 337-344.
[13] Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-test is antigen genes in gastrointestinal and breast carcinomas [J]. Br J Cancer, 2001, 85(5): 713-720.
[14] Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy [J]. Oncoimmunology, 2012, 2(10): 1111-1134.
[15] Paezesny S, Sift FI, Saito H, et a1.Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccine with a tumor inhibition assay in vitro [J].J lmmunolher, 2005, 28(2): 148-157.
[16] Shi H, Cao T, Connolly JE, et al. Hyperthermia enhances CTL cross-priming [J]. J Immunol, 2006, 176(4): 2134-2141.
[17] 虞淦军, 万涛. NY-ESO-1 抗原的基础与临床研究进展[J].中国肿瘤生物治疗杂志, 2015, 22(1): 104-111.
[18] 陈军, 尚小云, 唐波, 等. 胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J]. 第三军医大学学报, 2009, 31(10): 984-986.
[19] 吴晓江, 王俞欠, 季加孚,等.胃癌中肿瘤/睾丸抗原的表达研究及NY-ESO-1蛋白的自身抗体检测[J]. 北京大学学报(医学版), 2005, 37(3): 252-256.
[20] Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma [J]. Nat Med, 2015, 21(8): 914-921.
[21] Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions [J]. J Immunol, 2008, 180(9): 6116-6131.
[22] Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients[J]. J Exp Med, 2010, 207(10): 2175-2186.
[23] Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance [J]. Immunity, 2013, 39(1): 74-88.

相关文章 15

[1]	田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087.
[2]	马向波,张学武,贾汝琳,高颖,刘洪江,刘玉芳,李英妮. 外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用[J]. 北京大学学报（医学版）, 2021, 53(4): 721-727.
[3]	于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646.
[4]	李远骋, 崔闻心, 郭雪儿, 朱璠, 刘思辰, 贾碧波, 汪培, 马迎华. 青年学生男男性行为人群中人类免疫缺陷病毒阳性与阴性者获得性免疫缺陷综合征(艾滋病)相关知识与行为比较[J]. 北京大学学报（医学版）, 2021, 53(3): 511-517.
[5]	邱敏,费月阳,邓绍晖,刘承,卢剑,何为,陆敏,田晓军,张树栋,马潞林. 后肾腺瘤的诊治经验及文献回顾[J]. 北京大学学报（医学版）, 2021, 53(2): 417-419.
[6]	池彦廷,张延平,张秋露,刘翠苓,李斌斌. 唾液腺干燥综合征继发黏膜相关淋巴组织淋巴瘤的临床病理分析[J]. 北京大学学报（医学版）, 2021, 53(1): 40-45.
[7]	郑艺明,郝洪军,刘怡琳,郭晶,赵亚雯,张巍,袁云. Ro52抗体与其他肌炎抗体共阳性的相关性研究[J]. 北京大学学报（医学版）, 2020, 52(6): 1088-1092.
[8]	魏士雄,黎苏佳,刘毅. 幼年特发性关节炎成人后的临床特点及生物制剂治疗[J]. 北京大学学报（医学版）, 2020, 52(6): 1014-1022.
[9]	朱冯赟智,邢晓燕,汤晓菲,李依敏,邵苗,张学武,李玉慧,孙晓麟,何菁. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报（医学版）, 2020, 52(6): 995-1000.
[10]	禹琛,李春,范洋溢,徐燕. 白塞综合征合并急性格林巴利综合征1例[J]. 北京大学学报（医学版）, 2020, 52(6): 1146-1149.
[11]	程功,张霞,杨菲,程嘉渝,刘燕鹰. 以发热、关节炎、皮肤色素沉着为主要表现的血管免疫母细胞性T细胞淋巴瘤1例[J]. 北京大学学报（医学版）, 2020, 52(6): 1150-1152.
[12]	陈伟钱,戴小娜,余叶,王沁,梁钧昱,柯旖旎,易彩虹,林进. 原发性干燥综合征合并自身免疫性肝病的临床特点及预后分析[J]. 北京大学学报（医学版）, 2020, 52(5): 886-891.
[13]	胡宇晴,张建中. 156例特应性皮炎患者血清吸入和食物过敏原特异性免疫球蛋白E及患者自觉过敏情况[J]. 北京大学学报（医学版）, 2020, 52(5): 980-984.
[14]	李秋钰,程秦,赵志伶,代妮妮,曾琳,朱兰,郭炜,李超,王军红,李姝,葛庆岗,沈宁. 肾移植术后感染新型冠状病毒1例[J]. 北京大学学报（医学版）, 2020, 52(4): 780-784.
[15]	姜妮,乔国梁,王小利,周心娜,周蕾,宋雨光,赵艳杰,任军. 中性粒细胞与淋巴细胞比例对评估接受过继性细胞免疫治疗的晚期胰腺癌患者预后的临床意义[J]. 北京大学学报（医学版）, 2020, 52(3): 597-602.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed